A validated bioluminescence-based assay for the rapid determination of the initial rate of kill for discovery antimalarials

Article English OPEN
Ullah, I ; Sharma, R ; Biagini, G ; Horrocks, P (2016)
  • Publisher: Oxford University Press
  • Related identifiers: doi: 10.1093/jac/dkw449
  • Subject: wc_750 | qx_135 | qv_256 | qv_771 | qy_25 | wc_765 | R1
    mesheuropmc: parasitic diseases

Objectives: A future treatment for uncomplicated malaria will contain at least one component that exerts a rapid rate of kill. We describe here the validation and application of a simple, robust and rapid bioluminescence-based assay for the determination of the initial rate of kill in intra-erythrocytic asexual stages of Plasmodium falciparum.\ud \ud Methods: A modification to the concentration–response bioluminescence [here termed bioluminescence relative rate of kill (BRRoK)] assay, utilizing exposure to fold-IC50 concentrations (0.33× to  9×), was used to monitor the immediate cytocidal effect of 372 open-source compounds for antimalarial drug discovery available through the Medicines for Malaria Venture Malaria Box.\ud \ud Results: Antimalarial drugs that exert a rapid cytocidal effect produce a concentration-dependent loss of bioluminescence signal that correlates with available in vitro and in vivo estimates of parasite clearance time and parasite reduction ratio. Following the measurement of IC50 for the Malaria Box compounds in Dd2luc, the BRRoK assay was used to identify and rank 372 compounds for their initial cytocidal activity. Fifty-three compounds in the Malaria Box show an initial relative rate of kill greater than that of chloroquine, with 17 of these having an initial relative rate of kill greater than that of dihydroartemisinin.\ud \ud Conclusions: The BRRoK assay provides a rapid assay format for the estimation of a key pharmacodynamic property of antimalarial drug action. The simplicity and robustness of the assay suggests it would be readily scalable for high-throughput screening and a critical decision-making tool for antimalarial drug development.
  • References (33)
    33 references, page 1 of 4

    17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 5. Dondorp AM, Fairhurst RM, Slutsker L et al. The threat of artemisinin-resistant malaria. New Engl J Med 2011; 365: 1073-5.

    6. Noedl H, Se Y, Schaecher K et al. Evidence of artemisinin-resistant malaria in Western Cambodia. New Engl J Med 2008; 359: 2619-20.

    7. Tun KM, Imwong M, Lwin KM et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis 2015; 15: 415-21.

    8. Anthony MP, Burrows JN, Duparc S, et al. The global pipeline of new medicines for the control and elimination of malaria. Malar J 2012; 11: 316.

    9. Burrows JN, van Huijsduijnen RH, Mohrle JJ et al. Designing the next generation of medicines for malaria control and eradication. Malar J 2013; 12: 187.

    10. Gamo FJ, Sanz LM, Vidal J et al. Thousands of chemical starting points for antimalarial lead identification. Nature 2010; 465: 305-10.

    11. Guiguemde WA, Shelat AA, Bouck D et al. Chemical genetics of Plasmodium falciparum. Nature 2010; 465: 311-5.

    12. Plouffe D, Brinker A, McNamara C et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. PNAS (USA) 2008; 105: 9059-64.

    13. Sanz LM, Crespo B, De-Cozar C et al. P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode of action. PLoS One 2012; 7: e30949.

    14. Spangenberg T, Burrows JN, Kowalczyk P et al. The open access malaria box: a drug discovery catalyst for neglected diseases. PLoS One 2013; 8: e62906.

  • Related Research Results (3)
  • Metrics
    No metrics available
Share - Bookmark